LARIX BIOSCIENCE LLC
Sunnyvale, CA · Biotech · Private
Stable chimeric albumin- or IgG Fc-fused hormone biologics and hormone-based nanomedicines for enhanced tissue regeneration
- Grants
- $12M
- 39 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 2 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Human Glyco-engineered CHO Cells | $196,091 | |
| Federal grant | Department of Health and Human Services · Phase I · Human Glyco-engineered CHO Cells | $196,091 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel targeted therapeutic for advanced metastatic disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel targeted therapeutic for advanced metastatic disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel monobody therapy for pancreatic cancer | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase II · Human glyco-engineered CHO cells | $700,809 | |
| Federal grant | Department of Health and Human Services · Phase II · Human glyco-engineered CHO cells | $1,489,394 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for Goodpasture syndrome | $224,393 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for Goodpasture syndrome | $224,393 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for atopic dermatitis | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase II · Human glyco-engineered CHO cells | $788,585 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting innate immunity in Type 1 diabetes | $224,981 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Novel GPCR-targeted therapy for preeclampsia | $224,986 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Novel GPCR-targeted therapy for preeclampsia | $224,986 | |
| Federal grant | Department of Health and Human Services · Phase I · Dual Intracellular and Extracellular Expression Technology (dIEE) for AlzheimerÃÂâÃÂÃÂÃÂÃÂs Disease | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Dual Intracellular and Extracellular Expression Technology (dIEE) for Parkinson’s Disease | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Targeting TGF-beta activation in tumors | $224,981 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Targeting TGF-beta activation in tumors | $224,981 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel anti-fibrotic therapy for IPF | $224,924 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted therapeutic for Netherton syndrome | $252,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Therapy for Type 1 diabetes | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Inhibiting GPR146 in hypercholesterolemia | $249,734 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for myocardial ischemia-reperfusion injury | $252,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapy for myocardial ischemia-reperfusion injury | $252,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic antibody for cancer-associated cachexia | $252,282 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic antibody for anorexia nervosa | $259,606 | |
| Federal grant | Department of Health and Human Services · Phase I · Pan-COVID Therapeutic | $275,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Advancing a novel therapy for preeclampsia | $385,000 | |
| Federal grant | Department of Health and Human Services · Phase I · PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical | $275,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapeutic antibody for hyperemesis gravidarum | $300,847 | |
| Federal grant | Department of Health and Human Services · Phase I · Improved carnosic acid congener compounds for Alzheimer’s disease | $326,205 | |
| Federal grant | Department of Health and Human Services · Phase I · Pan-COVID Therapeutic Abstract Severe COVID-19 | $275,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Silencing autoantibody secretion for SLE therapy | $299,865 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapies for obesity- or diabetes-related lymphatic dysfunction | $245,728 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel therapies for obesity- or diabetes-related lymphatic dysfunction | $245,728 | |
| Federal grant | Department of Health and Human Services · Phase I · Overcoming pressure ulcers with engineered hormones and stem cells | $295,923 | |
| Federal grant | Department of Health and Human Services · Phase I · Overcoming pressure ulcers with engineered hormones and stem cells | $295,923 | |
| Federal grant | Department of Health and Human Services · Phase I · Therapy for ectopic calcification in pseudoxanthoma elasticum | $285,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Silencing autoantibody secretion for SLE therapy | $299,773 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1164 | YOURCHOICE THERAPEUTICS INC | — | — |
| 1165 | ABALONE BIO, INC. | — | — |
| 1166 | Arcus Biosciences | — | — |
| 1167 | LARIX BIOSCIENCE LLC | — | — |
| 1168 | Neumentum, Inc. | — | $27M |
| 1169 | Tioga Pharmaceuticals Inc | — | $24M |
| 1170 | KODIAK BP, LLC | — | $13M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Bispecific and trispecific functional molecules of ACE2 and complement pathways and their useapplication
- Methods And Compositions For Producing Double Allele Knock Outsgranted
- Methods And Compositions For Producing Double Allele Knock Outsgranted
- Methods And Compositions For Producing Double Allele Knock Outsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.